Please login to the form below

Not currently logged in
Email:
Password:

Heart drug

This page shows the latest Heart drug news and features for those working in and with pharma, biotech and healthcare.

UK heart deaths rise for first time in 50 years

UK heart deaths rise for first time in 50 years

Bayer recently teamed up with Imperial College London to explore the use of artificial intelligence in drug development, planning to develop machine learning tools such as 3D heart imaging, along with ... Meanwhile, drug giants such as Novartis and

Latest news

  • Amgen and UCB’s Evenity finally approved, but with label warnings Amgen and UCB’s Evenity finally approved, but with label warnings

    Drug unlikely to match Prolia's revenues. Amgen and UCB’s novel osteoporosis treatment Evenity has been approved by the FDA, nearly two years after it was first submitted. ... Evenity also carries a boxed warning on its label, which advises that the

  • Amgen, Servier heart failure drug clears trial hurdle Amgen, Servier heart failure drug clears trial hurdle

    Amgen and Servier have inched closer to a verdict on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their first phase 3 study passed a futility review. ... side of the heart isn't able to pump blood out to the body effectively.

  • AZ says Brilinta hits the mark in diabetic heart disease AZ says Brilinta hits the mark in diabetic heart disease

    The drug can reduce cardiovascular events in diabetics with CAD. AstraZeneca has chalked up another clinical trial win for its antiplatelet drug Brilinta, showing that it can reduce cardiovascular events in ... Brilinta is already approved to reduce risk

  • Amgen, Servier start second phase 3 trial of heart failure hope Amgen, Servier start second phase 3 trial of heart failure hope

    The lack of new drug treatment options in heart failure is one reason why survival rates remain stubbornly low and are lagging behind the big improvements seen with other diseases such ... One advance in drug treatment was the launch of Novartis’

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    Includes new gene therapy Zolgensma. Novartis has posted a 5% increase in its sales in 2018, driven up by strong performances by psoriasis blockbuster Cosentyx and heart failure drug Entresto. ... Entresto - Heart failure with preserved ejection fraction

More from news
Approximately 1 fully matching, plus 178 partially matching documents found.

Latest Intelligence

  • Transforming Access to Medicines Through Patient-Centric Solutions Transforming Access to Medicines Through Patient-Centric Solutions

    to medicines and the importance of putting patients at the heart of drug development and access. ... Patients at the heart of drug development and access. If you believe the news every day, patients are becoming more and more involved in drug development

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. ... After a heart attack people tend to leave the hospital thinking the event is over.

  • Closing the treatment gap

    Statins are one of the medical success stories of the 20th century, used by millions of people to lower blood cholesterol levels and reduce their risk of heart disease. ... This included a global release available at the press event and distribution over

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics